Arthur A. Levin - Mar 15, 2023 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role
Director
Signature
/s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
Stock symbol
RNA
Transactions as of
Mar 15, 2023
Transactions value $
-$2,077
Form type
4
Date filed
3/17/2023, 04:36 PM
Previous filing
Feb 15, 2023
Next filing
Jun 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNA Common Stock Options Exercise $124 +100 +0.52% $1.24* 19.4K Mar 15, 2023 Direct F1
transaction RNA Common Stock Sale -$2.2K -100 -0.51% $22.01 19.3K Mar 15, 2023 Direct F1
holding RNA Common Stock 274K Mar 15, 2023 By family trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -100 -0.15% $0.00 68.3K Mar 15, 2023 Common Stock 100 $1.24 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter.